Oncology Institute (NASDAQ:TOI) Major Shareholder Jorey Chernett Purchases 5,000 Shares

The Oncology Institute, Inc. (NASDAQ:TOI) major shareholder Jorey Chernett acquired 5,000 shares of Oncology Institute stock in a transaction that occurred on Tuesday, May 19th. The stock was acquired at an average price of $4.05 per share, with a total value of $20,250.00. Following the completion of the purchase, the insider directly owned 10,534,358 shares in the company, valued at $42,664,149.90. This represents a 0.05% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Wednesday, May 20th, Jorey Chernett bought 33,500 shares of Oncology Institute stock. The shares were bought at an average price of $4.07 per share, for a total transaction of $136,345.00.
• On Tuesday, May 19th, Jorey Chernett purchased 30,000 shares of Oncology Institute stock. The stock was bought at an average cost of $4.09 per share, with a total value of $122,700.00.
• On Thursday, April 9th, Jorey Chernett purchased 20,000 shares of Oncology Institute stock. The stock was bought at an average price of $3.10 per share, with a total value of $62,000.00.
• On Tuesday, March 24th, Jorey Chernett acquired 125,000 shares of Oncology Institute stock. The shares were bought at an average price of $3.11 per share, for a total transaction of $388,750.00.
• On Friday, March 20th, Jorey Chernett acquired 25,000 shares of Oncology Institute stock. The shares were bought at an average cost of $3.35 per share, for a total transaction of $83,750.00.
• On Tuesday, March 17th, Jorey Chernett bought 75,000 shares of Oncology Institute stock. The stock was bought at an average price of $3.42 per share, with a total value of $256,500.00.
• On Monday, March 16th, Jorey Chernett bought 60,985 shares of Oncology Institute stock. The shares were bought at an average cost of $3.29 per share, with a total value of $200,640.65.
• On Friday, March 13th, Jorey Chernett bought 263,000 shares of Oncology Institute stock. The shares were bought at an average cost of $2.92 per share, with a total value of $767,960.00.

Oncology Institute Stock Up 6.4%

Shares of TOI opened at $4.47 on Friday. The Oncology Institute, Inc. has a twelve month low of $2.02 and a twelve month high of $4.88. The stock has a market cap of $441.81 million, a PE ratio of -12.08 and a beta of 0.33. The business’s 50-day moving average price is $3.47 and its 200-day moving average price is $3.32.

Oncology Institute (NASDAQ:TOI) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.05. The firm had revenue of $147.44 million during the quarter, compared to the consensus estimate of $142.10 million. Analysts expect that The Oncology Institute, Inc. will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC purchased a new position in Oncology Institute in the fourth quarter worth $31,000. Pekin Hardy Strauss Inc. purchased a new stake in Oncology Institute during the fourth quarter valued at about $36,000. R Squared Ltd purchased a new stake in Oncology Institute during the fourth quarter valued at about $41,000. Prelude Capital Management LLC purchased a new stake in Oncology Institute during the third quarter valued at about $41,000. Finally, BNP Paribas Financial Markets boosted its position in Oncology Institute by 141.0% during the third quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock valued at $42,000 after buying an additional 7,091 shares during the period. 36.86% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TOI has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a research report on Monday, April 20th. BTIG Research restated a “buy” rating and issued a $7.00 target price on shares of Oncology Institute in a research note on Monday, March 9th. B. Riley Financial upped their target price on Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $5.00 target price on shares of Oncology Institute in a research note on Monday, March 9th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Oncology Institute presently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.